Allan Kalmus
Foot Surgery · Taylor, MINPI 1659360212
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.4% of the total across 60 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations.
Across 60 payments — averaging $70.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acumed LLC$762
- Bone Support Inc.$644
- Treace Medical Concepts, Inc.$605
- Osteomed LLC$422
- Stryker$326
- Kuros Biosciences USA, Inc$224
- plus $1K from 21 others
What the payments were for
- Food & beverage$4,08296%
- Education$1544%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acumed LLC | 9 | $762 |
| Bone Support Inc. | 6 | $644 |
| Treace Medical Concepts, Inc. | 5 | $605 |
| Osteomed LLC | 6 | $422 |
| Stryker(2 entities) | 3 | $326 |
| Kuros Biosciences USA, Inc | 2 | $224 |
| Kerecis Limited | 1 | $165 |
| Johnson & Johnson | 2 | $155 |
| Novo Nordisk | 1 | $125 |
| Sequel Med Tech, LLC | 1 | $124 |
| Medtronic | 1 | $111 |
| Nevro Corp. | 3 | $106 |
| Paragon 28, Inc. | 1 | $68 |
| Arthrosurface Incorporated | 1 | $66 |
| Averitas Pharma Inc. | 3 | $51 |
| Verity Pharmaceuticals Inc. | 2 | $38 |
| Ultragenyx Pharmaceutical Inc. | 2 | $34 |
| Linvatec Corporation | 1 | $34 |
| Recordati_rare_diseases_inc. | 2 | $34 |
| Corcept Therapeutics | 1 | $22 |
| Amgen | 1 | $20 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Smith+Nephew | 1 | $18 |
| Surgenex LLC | 1 | $18 |
| Boston Scientific | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| GRT US Holding, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACUMED$1,404
- Kerecis Omega3 Marigen$658
- CERAMENTBONE VOID FILLER$561
- CERAMENT G$561
- Lapiplasty System$485
- OsteoMed$347
- MagnetOs$224
- AUGMENT INJECTABLE$171
- T2$171
- VALOR$171
- Kerecis Omega3 SurgiClose$165
- Saxenda$125
- TWIIST$124
- VARIAX$123
- FIXOS$123
- TMC NANOPLASTY SYSTEM$120
- VenaSeal$111
How this compares
$4,236 in reported general payments places this provider in the 70th percentile of 22 foot surgery providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| QutenzaCapsaicin/Skin Cleanser | 11 | $38,861 |
| Ammonium Lactate | 341 | $5,320 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 58 | $684 |
| Mupirocin | 85 | $567 |
| Ketoconazole | 24 | $326 |
| Pentoxifylline | 14 | $218 |
| Gabapentin | 35 | $205 |
| Terbinafine Hcl | 19 | $183 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GRT US Holding, Inc.Qutenza | $13 | $38,86111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 22 foot surgery providers in Michigan.
Other foot surgery in Taylor
- Vicki Anton AthensBrownstown Twp$16K
- Katherine MorrisonSouthfield$12K
- Ellen MadyWest Bloomfield$6K
- Abbas BaghdadiClinton Township$6K
- Travis PiperMuskegon$5K
- James HillBrownstown Twp$5K
- Roger DeyoungMuskegon$2K
- Jan SmolenMuskegon$2K
- Harold SterlingLansing$1K
- Laal ZadaBrownstown Twp$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.